The Use of ATP-MgCl2 in the Treatment of Injury and Shock.
Abstract
Our objectives were to determine the safety and hemodynamic response of Adenosine Triphosphate-Magnesium Chloride (ATP-MGCL2) infusion in normal awake human volunteers. Five healthy adult male volunteers received an intravenous infusion of ATP-MGCL2 (0.1-0.4mg/kg/min) on four separate occasions. The totals dose infusion was 3,6,10 and 30mg/kg. Hemodynamic measurements were made at end exhalation in the supine position and included heart rate and systolic, diastolic and mean blood pressure. Continuous electrocardiographic monitoring of lead II was performed. Cardiac output was determined by injection of indocyanine green and measured by the principle of earpiece densitometry. Blood samples were obtained for determination of hemoglobin, sodium, potassium and glucose. Stroke volume index (SVI) and total systemic resistance (TSR) were derived from standard formulae. The results indicated that cardiac output increased by 76% from control values with ATP-MGCL2 infusion. This increase in cardiac output correlated positively with ATP-MGCL2 infusion rate. This was paralleled by a 45% increase in heart rate. SVI increased by 14%, however, the mean blood pressure did not change significantly over the entire range of infusion rates. TSR decreased 56% at the highest rate of ATP-MGCL2 infusion. A mean infusion rate of 0.32 + 0.02 mg/kg/min was associated with maximal increases in heart rate (52%) and cardiac output (119%) without affecting mean blood pressure. Hemodynamic effects were poorly correlated with total dose of ATP-MGCL2. ATP-MGCL2 is a potent vasodilator.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 31, 1986
- Accession Number
- ADA186765
Entities
People
- Irshad H. Chaudry
Organizations
- Yale University